"in a way never seen before.”

 5-16-21 by Charles Faddis
  In 1996 two Chinese air force officers, Qiao Liang and Wang Xiangsui produced a seminal book entitled Chao Xian Zhan: Dui Quanqiu Hua Shidai Zhanzheng yu Zhanfa de Xiangding (Warfare Beyond Rules: Judgment of War and Methods of War in the Era of Globalization).  It was published by the People’s Liberation Army (PLA).
  The central premise of the book, which has largely guided Chinese defense thought since, was that Western, imperialist powers had created the law of war in order to handicap other nations.
  In 2010 a book called War for Biological Dominance was published by Xinhua Publishing House.  It was authored by Guo Jiwei, professor and chief physician at the People’s Liberation Army’s Third Military Medical University.  This work expanded on the idea that biological warfare should be part of any future conflict waged by Communist China.
  In 2015 the idea of biological warfare was taken to the next level by then-president of the Academy of Military Medical Sciences, He Fuchu, who argued in an essay that biotechnology would be the deciding factor in any future war. Biological warfare was not just permissible. It would one of the keys to victory.
  A document written by Chinese scientists and Chinese public health officials in 2015 specifically discussed the weaponization of SARS coronavirus.  Entitled The Unnatural Origin of SARS and New Species of Man-Made Viruses as Genetic Bioweapons, the paper predicted that World War Three would be fought with bioweapons.  This work specifically identified SARS coronaviruses as a “new era of genetic weapons” that can be “artificially manipulated into an emerging human disease virus, then weaponized and unleashed in a way never seen before.”  
https://accountabilityinitiative.org/paying-people-to-kill-us-chinas-focus-on-biological-warfare/
………………………..................
104 Carnegie Center Drive, Suite 204,
Princeton, NJ 08540
(609)250-2875
info.usa@fosunpharma.com
…………………………..
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (trade name: Fosun Pharma) is a Chinese pharmaceutical company.  It is mostly owned by Fosun International.[2]    

Key people
    •    Wu Yifang is the president and CEO of Fosun Pharma.[5]
    Chen Qiyu is co-CEO of Fosun International and Chairman of Fosun Pharma.                       On March 17, 2020, BioNTech received a $135 million investment from Fosun in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of the mRNA vaccine BNT162b2 in China.[28] Also, BioNTech announced a collaboration with Pfizer to scale-up manufacturing capacity to provide worldwide supply in response to the pandemic.   https://en.wikipedia.org/wiki/Fosun_Pharma
………………………………………
BEIJING, May 9, 2021 (Reuters) - China's Shanghai Fosun Pharmaceutical  said its subsidiary has agreed to provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine developed by BioNTech.  https://www.reuters.com/business/healthcare-pharmaceuticals/fosun-pharma-provide-factory-with-annual-capacity-1-bln-doses-biontechs-covid-19-2021-05-09/
…………………………….
Published: 28 June 2021
Use of nanotechnology in combating coronavirus
Abstract
 The use of nanotechnology and nanomedicine has been considered to be promising due to its excellent potential in managing various medical issues such as viruses which is a major threat. Nanoparticles have shown great potential in various biomedical applications and can prove to be of great use in antiviral therapy, especially over other conventional antiviral agents.  This review focusses on the pathophysiology of SARS-CoV-2 and the progression of the COVID-19 disease followed by currently available treatments for the same.  Use of nanotechnology has been elaborated by exploiting various nanoparticles like metal and metal oxide nanoparticles, carbon-based nanoparticles, quantum dots, polymeric nanoparticles as well as lipid-based nanoparticles along with its mechanism of action against viruses which can prove to be beneficial in COVID-19 therapeutics.  https://link.springer.com/article/10.1007/s13205-021-02905-6
…………………………………….

8-9-21   A former Pfizer employee and current analyst for the pharmaceutical and medical device industries, came forward with indisputable documentation proving that GRAPHENE OXIDE NANOPARTICLES is the key ingredient in Biotech’s Covid-19 serums.
  This means that an unapproved industrial poison is being dishonestly marketed as “vaccines” and injected into peoples’ veins.
In her must-watch interview with Stew Peter’s on July 28th, Kingston reveals how graphene oxide was hidden under a trade secret.  It was therefore not recorded in Biotech’s patent filing as an ingredient in the Covid-19 serums.  It was also not disclosed to the public Kingston explains, because it was not required due to it being the registered intellectual property of the pharmaceutical cartel.
  Prior to the Stew Peters interview, Karen Kingston did a series of four additional interviews with Doug Billings on The Right Side.  These are all well worth listening to.
Graphene oxide has never been used on humans before but it’s been extensively researched for intended use on humans.  There are over 2000 studies on graphene oxide toxicity and 500 of them were published in 2017.
  On August 5th, Kingston gave another crucial interview with Dr. Andrew Kaufman on the Alex Jones Show where they showed us documents confirming without a shadow of a doubt that Biotech’s Covid-19 jabs include graphene oxide and lipid-coated nanoparticles.  
  Dr. Kaufman showed a study entitled, Graphene oxide-incorporated hydrogels for biomedical applications, revealing that graphene oxide has been developed for biomedical gene and drug delivery under the EU’s “Graphene Flagship” which I wrote about here.
  Under the one billion euros EU project, gene delivery for an intranasal SARS-Cov-2 flu vaccine was tested using… wait for it… graphene oxide!
  A patent from China was filed and approved last year, using graphene oxide nanotechnology in gene and drug delivery and diagnostic purposes for… wait for it… a “coronavirus vaccine”!
  There are a couple dozen articles describing the use of lipid-nanoparticles and graphene oxide for ovarian cancer treatment using gene therapy, Kingston points out.  Moderna was in fact, researching and developing graphene oxide for cancer treatment. Moderna is specialized in cancer cures, not vaccines.  Moderna was an oncology cancer therapy company.    

  Graphene was considered a “wonder material” due to its never-before-seen properties. It’s the strongest material known to man with 1000 times the strength of titanium and yet, it’s nano-particularized.
  Graphene oxide is super-elastic and highly conductive, enabling it to enter even the brain. Its potential applications in biomedicine were enormous and a multibillion-dollar industry was looming that could revolutionize the diagnostic and treatment of diseases.
  Moderna, Pfizer/BioNTech, etc, were in a race to research and development graphene oxide nanoparticles as a cancer cure. So, graphene oxide was injected into animals and used as the vector to deliver a novel mRNA drug technology directly into cells.  At first the animals seemed fine and the cancer cells were successfully destroyed. But two months after inoculation all the animals got sick and DIED from Antibody-Dependent Enhancement (ADE)! Healthy cells were destroyed by the graphene oxide nanoparticles. Safety and toxicity were the pharma cartel’s main challenges in using this novel technology for biomedical applications such as gene therapy.
  After two animal trials that resulted in the death of all the animals, graphene oxide could not be approved for use in humans due to its toxicity to healthy cells and due to ADE, which is where the immune system destroys itself.
  Frontline doctors are already seeing ADE in these unapproved Covid-19 human trials.  Experts such as Europe’s leading virologist Professor Dolores Cahill, world-renown scientist Mike Adams of Natural News, world’s leading virologist Geert Vanden Bossche and Pfizer whistleblower, Dr. Michael Yeadon warned us that ADE would come! …
  According to the animal studies, the pharma cartel also knew that graphene oxide enables “self-replicating vaccines“; aka transmission.
  This essentially means that the pharma cartel is falsely marketing gene therapies as “vaccines” in order to profit by injecting an unapproved industrial chemical into humans without their Informed Consent.  That is in direct violation of the Nuremberg Laws.  Is it apparent now that the pharma cartel is determined to profit anyhow, at the expense of all our lives?
I encourage you to read my article entitled, Graphene Oxide The Vector For Covid-19 Democide, which has added vital information about human exposure to graphene oxide nanoparticles.  https://ambassadorlove.wordpress.com/2021/08/09/confirmed-graphene-oxide-main-ingredient-in-covid-shots/
……………….......................

5-18-2020, thereafter updated.      BioNTech, Pfizer, and Fosun Pharma – COMIRNATY® (BNT162b2) 
Type:  Nucleoside modified mRNA (modRNA) candidate encoding an optimized SARS-CoV-2 full-length spike protein antigen. COMIRNATY is the lead candidate of the Pfizer/BioNTech BNT162 program, which includes another modRNA candidate that encodes an optimized SARS-CoV-2 receptor-binding domain (RBD) antigen antigen; a uridine containing mRNA (uRNA) candidate; and a candidate using self-amplifying mRNA (saRNA).  The other candidates are known as BNT162a1, BNT162b1, and BNT162c2.
  Each mRNA format is combined with a lipid nanoparticle (LNP) formulation.  The larger spike sequence is included in two of the candidates, while the smaller optimized receptor binding domain (RBD) from the spike protein is included in the other two candidates.
  2021 Status:  Booster Dose Shows 95.6% Efficacy
Europe, Canada Review Authorization for Ages 5-11–The European Medicines Agency (EMA) and Health Canada said October 18 that they received submissions from Pfizer-BioNTech seeking authorizations for the use of its Comirnaty COVID-19 vaccine in children 5 to 11 years of age.
EMA said its human medicines committee (CHMP) will review data and issue an opinion to be forwarded to the European Commission, which will issue a final decision.
  EUA Expansion Sought for Children Ages 5-11  FDA Panel to Mull Expanded EUA for Kids 5-11
EMA Eyes Booster Decision in October—Marco Cavaleri, PhD, the European Medicines Agency (EMA)’s Head of Biological Health Threats and Vaccines Strategy, said at a September 23 press briefing that his agency is assessing whether to endorse a third dose of COMIRNATY, to be administered six months after the second dose: “The outcome of this evaluation is expected in early October, unless supplementary information is needed.”
  500M More Doses for Donation—Pfizer and BioNTech said September 22 that they will expand their three-month-old agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at an undisclosed not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them….The current plan is to produce the doses in Pfizer’s U.S. facilities located in Kalamazoo, MI, Andover, MA, Chesterfield, MO, and McPherson, KS….
While the vaccine will be distributed under the brand name COMIRNATY, the companies said, Canada will continue to receive vials of the vaccine labeled as Pfizer-BioNTech COVID-19 Vaccine.  The formulation for Pfizer-BioNTech COVID-19 Vaccine is the same formulation as COMIRNATY and they are considered interchangeable by Health Canada.
  Brazil Manufacturing Agreement—Pfizer and BioNTech said August 26, 2021 they signed a letter of intent with the Brazilian biopharma Eurofarma Laboratórios to manufacture COMIRNATY for distribution within Latin America. …
Pfizer plans to deliver 3 billion doses in total by the end of 2021.
  EU OKs Manufacturing Increase—The European Medicines Agency (EMA) said August 24 that its human medicines committee (CHMP) had approved an additional manufacturing site for the production of Comirnaty in Saint Rémy sur Avre, France. The site, operated by Delpharm, will enable the manufacture of approximately up to 51 million additional doses in 2021. The EMA also approved a new line at BioNTech’s manufacturing site in Marburg, Germany, that will increase its active substance manufacturing capacity by approximately 410 million doses in 2021.
  FDA ISSUES FULL APPROVAL—Pfizer and BioNTech on August 23 received the FDA’s first formal approval for a COVID-19 vaccine when the agency approved the companies’ Biologics License Application for BNT162b2, which according to the FDA will be marketed going forward as Comirnaty, its brand name in Europe.
  FDA Reportedly Accelerating Review of Full Approval—The FDA’s Center for Biologics Evaluation will deprioritize some existing work in order to accelerate its review of the Pfizer/BioNTech BLA application for BNT162b2, STAT reported on July 30, citing an unnamed senior agency official who characterized the upcoming review as a “sprint.” CBER Director Peter Marks, MD, PhD, will “largely” oversee review of the application in place of Marion F. Gruber, PhD, Director of CBER’s Office of Vaccines Research and Review, according to the report.
  200M More U.S. Doses—Pfizer and BioNTech said July 23 that the U.S. government had purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine for an undisclosed price, bringing the total number of doses to be supplied by the companies to the U.S. government to 500 million. .
BNT162b2, AstraZeneca Vaccines Effective vs. Delta—In a study published July 21 in The New England Journal of Medicine, a team of U.K. researchers reported that two doses of Pfizer/BioNTech’s BNT162b2 were 88% effective at preventing symptomatic disease from the delta variant of SARS-CoV-2, compared to 93.7% against the alpha variant. AstraZeneca’s COVID-19 vaccine showed a two-dose effectiveness of 74.5% among persons with the alpha variant and 67% among those with the delta variant.
  African Union Distribution Agreement—Pfizer and BioNTech said July 21 that they signed a letter of intent with The Biovac Institute, a CapeTown, South Africa biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within the African Union.
  Up to 1.8B Additional Doses for E.U.—Pfizer and BioNTech said May 20 they agreed with the European Commission to supply the E.U. with 900 million additional doses of COMIRNATY®, with an option for the EC to request a further 900 million doses.
  60M More Doses for Turkey—Pfizer and BioNTech said May 20 it entered into an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses.       A week earlier on January 8, the European Medicines Agency approved raising the number of doses drawn from each vial from five to six, a 20% increase in the number of available doses.
Also that day, researchers from Pfizer and the University of Texas Medical Branch (UTMB) posted results from an in vitro  study on the preprint server bioRxiv showing that antibodies from people who have received COMIRNATY effectively neutralize SARS-CoV-2 with the N501Y mutation that is also found in two highly transmissible strains. A virus with the mutation was generated in UTMB’s laboratory. The sera of 20 participants from the Phase III trial neutralized the virus with the mutation as well as neutralized virus without the mutation. https://www.genengnews.com/covid-19-candidates/biontech-pfizer-and-fosun-pharma-bnt162/
…………………………..